These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33896060)

  • 21. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain.
    Kromminga A; Sitaru C; Meyer J; Arndt R; Schmidt E; Christophers E; Bröcker EB; Zillikens D
    J Dermatol Sci; 2002 Jan; 28(1):68-75. PubMed ID: 11916132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
    Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
    Charneux J; Lorin J; Vitry F; Antonicelli F; Reguiai Z; Barbe C; Tabary T; Grange F; Bernard P
    Arch Dermatol; 2011 Mar; 147(3):286-91. PubMed ID: 21422334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
    Fairley JA; Fu CL; Giudice GJ
    J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
    Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
    Front Immunol; 2021; 12():569287. PubMed ID: 33841390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180.
    Perriard J; Jaunin F; Favre B; Büdinger L; Hertl M; Saurat JH; Borradori L
    J Invest Dermatol; 1999 Feb; 112(2):141-7. PubMed ID: 9989787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.
    Imafuku K; Iwata H; Kamaguchi M; Izumi K; Natsuga K; Ujiie H; Nishie W; Shimizu H
    Exp Dermatol; 2017 Dec; 26(12):1171-1174. PubMed ID: 28266727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels of D-dimer and fibrin degradation products correlate with bullous pemphigoid severity: a cross-sectional study.
    Wang S; Lu M; Zhao Z; Peng X; Li L; Cheng C; Fang M; Xia Y; Liu Y
    Sci Rep; 2021 Sep; 11(1):17746. PubMed ID: 34493780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies.
    Zillikens D; Rose PA; Balding SD; Liu Z; Olague-Marchan M; Diaz LA; Giudice GJ
    J Invest Dermatol; 1997 Oct; 109(4):573-9. PubMed ID: 9326393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Schmidt E; Obe K; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Feb; 136(2):174-8. PubMed ID: 10677092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.
    Masmoudi W; Vaillant M; Vassileva S; Patsatsi A; Quereux G; Moltrasio C; Abasq C; Prost-Squarcioni C; Kottler D; Kiritsi D; Litrowski N; Plantin P; Friedrichsen L; Zebrowska A; Duvert-Lehembre S; Hofmann S; Ferranti V; Jouen F; Joly P; Hebert V;
    Br J Dermatol; 2021 Jun; 184(6):1106-1112. PubMed ID: 33067805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
    Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
    J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.
    Clapé A; Muller C; Gatouillat G; Le Jan S; Barbe C; Pham BN; Antonicelli F; Bernard P
    Front Immunol; 2018; 9():479. PubMed ID: 29662486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological features and factors associated with mucocutaneous bullous pemphigoid - a retrospective cohort study.
    Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1289-1295. PubMed ID: 34164921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients.
    Di Zenzo G; Grosso F; Terracina M; Mariotti F; De Pità O; Owaribe K; Mastrogiacomo A; Sera F; Borradori L; Zambruno G
    J Invest Dermatol; 2004 Jan; 122(1):103-10. PubMed ID: 14962097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.
    Nakatani C; Muramatsu T; Shirai T
    Br J Dermatol; 1998 Sep; 139(3):365-70. PubMed ID: 9767278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.
    Thoma-Uszynski S; Uter W; Schwietzke S; Schuler G; Borradori L; Hertl M
    J Immunol; 2006 Feb; 176(3):2015-23. PubMed ID: 16424234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.